|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Partnerships: Bargaining Biotechs
Author(s)Kevin Gopal
Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.
Advertisement
Articles in this issue
over 24 years ago
Internet DTC - Minding Your P's & Q'sover 24 years ago
Regulation: Two-Track Planover 24 years ago
Policy: Tectonic Shiftover 24 years ago
Liberated?over 24 years ago
A Matter of Tasteover 24 years ago
Pediatric Mandateover 24 years ago
Genentech's Passion for Patientsover 24 years ago
Regulation: OK After AllNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
3
AI Built for Pharma—Out-of-the-Box Wins on Time, Risk, and ROI
4
FDA Announces New Biosimilar-Targeted Draft Guidance
5
